News & media

Press releases & publications.

News about BioGenomics, and the research we publish.

Approval · September 2025

Our insulin aspart mix is approved in India.

In September 2025, our insulin aspart mix, a pre-mixed insulin analogue, was approved in India. It follows our insulin aspart, which patients in India have used since October 2023 under the brand name InsuQuick™. Launch of insulin aspart mix in India is planned.

Publications

Our research, peer reviewed.

Our peer-reviewed papers on insulin aspart, from laboratory characterisation to clinical studies.

Pharmacokinetics and pharmacodynamics · 2025

Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin Aspart

Dongre SA, Kulkarni GA, Thapa D, Ghade N, Lona J, Prajapati H, et al. Clinical Pharmacology in Drug Development. 2025;14(3):209–216.

Read the paper

Phase III study · 2024

Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study

Dongre SA, Kulkarni GA, Mishra A, Deshmane RB, Sonar N, Yashi K, et al. Research in Pharmaceutical Sciences. 2024;19(5):489–499.

Read the paper

Immunogenicity · 2024

Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus

Mishra A, Dongre S, Kulkarni G, Deshmane R, Thappa D, Ghade N, et al. Journal of Endocrinological Investigation. 2024;47(6):1435–1446.

Read the paper

Physicochemical and structural characterisation · 2024

Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL‑ASP and reference insulin aspart

Ghade NS, Thappa DK, Lona J, Krishnan AR, Sonar SM. Scientific Reports. 2024;14:4224.

Read the paper

In vitro biological characterisation · 2023

In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart

Mishra AG, Deshmane RB, Thappa DK, Lona J, Ghade NS, Sonar SM, et al. BioDrugs. 2023;37(5):709–719.

Read the paper

Conference posters

Presented at the IDF World Diabetes Congress 2025 in Bangkok (7–10 April 2025). Select a poster to open it.

E-poster · Abstract BA2025-0212

Biological assays: key to successful development of insulin biosimilar for clinical application

Mishra A, Dongre S, Kulkarni G, Deshmane R, Thappa D, Ghade N, et al.

E-poster · Abstract BA2025-0274

Comparative bioassay of biphasic insulin aspart mix 30 of BioGenomics with NovoMix® 30 of Novo Nordisk

Deshmane R, Mishra A, Thappa D, Lona J, Ghade N, Kokatam S, et al.